GlassScriptPhysician profile
Edward P Secunda
NPI 1053337782
$3,356.85
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $1,569 · 2021: $449 · 2022: $14.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $500.79 | 2019-2020 | |
| Glaxosmithkline, LLC. | $467.86 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $326.69 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $290.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $252.13 | 2019-2021 | |
| Merz North America, INC. | $179.11 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.46 | 2019-2021 | |
| Amarin Pharma, INC. | $145.80 | 2019-2021 | |
| Antares Pharma, INC. | $135.60 | 2019 | |
| Pfizer INC. | $90.71 | 2019-2020 | |
| Abbvie INC. | $88.51 | 2020-2021 | |
| Allergan, INC. | $84.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $76.21 | 2019-2021 | |
| Daiichi Sankyo INC. | $72.30 | 2019-2020 | |
| Lilly USA, LLC | $55.12 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $50.01 | 2020 | |
| Jazz Pharmaceuticals INC. | $41.68 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $34.76 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $30.22 | 2019 | |
| Vivus LLC | $28.73 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $24.97 | 2020-2021 | |
| Pacira Therapeutics, INC. | $24.71 | 2020 | |
| Amgen INC. | $23.12 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.94 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $21.38 | 2020 | |
| Genentech USA, INC. | $18.82 | 2020 | |
| Eisai INC. | $16.53 | 2020 | |
| Circassia INC. | $16.23 | 2019 | |
| Hologic Sales and Service, LLC | $15.10 | 2020 | |
| Vanda Pharmaceuticals INC. | $14.95 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.90 | 2020 | |
| Phadia US INC. | $11.82 | 2019 | |
| Merck Sharp & Dohme LLC | $11.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Secunda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.